Literature DB >> 23991292

Is tail vein injection a relevant breast cancer lung metastasis model?

Omar M Rashid1, Masayuki Nagahashi, Suburamaniam Ramachandran, Catherine I Dumur, Julia C Schaum, Akimitsu Yamada, Tomoyoshi Aoyagi, Sheldon Milstien, Sarah Spiegel, Kazuaki Takabe.   

Abstract

BACKGROUND: TWO MOST COMMONLY USED ANIMAL MODELS FOR STUDYING BREAST CANCER LUNG METASTASIS ARE: lung metastasis after orthotopic implantation of cells into the mammary gland, and lung implantations produced after tail vein (TV) injection of cells. Tail vein injection can produce lung lesions faster, but little has been studied regarding the differences between these tumors, thus, we examined their morphology and gene expression profiles.
METHODS: Syngeneic murine mammary adenocarcinoma, 4T1-luc2 cells, were implanted either subcutaneously (Sq), orthotopically (OS), or injected via TV in Balb/c mice. Genome-wide microarray analyses of cultured 4T1 cells, Sq tumor, OS tumor, lung metastases after OS (LMet), and lung tumors after TV (TVt) were performed 10 days after implantation.
RESULTS: Bioluminescence analysis demonstrated different morphology of metastases between LMet and TVt, confirmed by histology. Gene expression profile of cells were significantly different from tumors, OS, Sq, TVt or LMet (10,350 probe sets; FDR≤1%; P<0.0001). Sq tumors were significantly different than OS tumors (700 probe sets; FDR≤15%; P<0.01), and both tumor types (Sq and OS) were significantly different than LMet (1,247 probe sets; >1.5-fold-change; P<0.01), with no significant difference between TVt and LMet.
CONCLUSIONS: There were significant differences between the gene profiles of cells in culture and OS versus LMet, but there were no differences between LMet versus TVt. Therefore, the lung tumor generated by TVt can be considered genetically similar to those produced after OS, and thus TVt is a relevant model for breast cancer lung metastasis.

Entities:  

Keywords:  Breast cancer; animal model; lung metastasis; metastasis model; microarray

Year:  2013        PMID: 23991292      PMCID: PMC3755653          DOI: 10.3978/j.issn.2072-1439.2013.06.17

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  50 in total

Review 1.  Orthotopic is orthodox: why are orthotopic-transplant metastatic models different from all other models?

Authors:  R M Hoffman
Journal:  J Cell Biochem       Date:  1994-09       Impact factor: 4.429

Review 2.  Lymphangiogenesis: a new player in cancer progression.

Authors:  Masayuki Nagahashi; Subramaniam Ramachandran; Omar M Rashid; Kazuaki Takabe
Journal:  World J Gastroenterol       Date:  2010-08-28       Impact factor: 5.742

3.  In situ transduction of cytosine deaminase gene followed by systemic use of 5-fluorocytosine inhibits tumor growth and metastasis in orthotopic prostate cancer mouse models.

Authors:  Zhengwang Zhang; Lianhua Yin; Yongkang Zhang; Fengdi Zhao
Journal:  Chin Med J (Engl)       Date:  2002-02       Impact factor: 2.628

4.  A fluorescent orthotopic bone metastasis model of human prostate cancer.

Authors:  M Yang; P Jiang; F X Sun; S Hasegawa; E Baranov; T Chishima; H Shimada; A R Moossa; R M Hoffman
Journal:  Cancer Res       Date:  1999-02-15       Impact factor: 12.701

Review 5.  Matrix metalloproteinases and their role in pancreatic cancer: a review of preclinical studies and clinical trials.

Authors:  Mark Bloomston; Emmanuel E Zervos; Alexander S Rosemurgy
Journal:  Ann Surg Oncol       Date:  2002-08       Impact factor: 5.344

6.  Growth and metastatic behavior of human tumor cells implanted into nude and beige nude mice.

Authors:  S Naito; R Giavazzi; S M Walker; K Itoh; J Mayo; I J Fidler
Journal:  Clin Exp Metastasis       Date:  1987 Apr-Jun       Impact factor: 5.150

Review 7.  Trials, tribulations, and trends in tumor modeling in mice.

Authors:  JoAnn C L Schuh
Journal:  Toxicol Pathol       Date:  2004 Mar-Apr       Impact factor: 1.902

Review 8.  Animal models of bone metastasis.

Authors:  Thomas J Rosol; Sarah H Tannehill-Gregg; Bruce E LeRoy; Stefanie Mandl; Christopher H Contag
Journal:  Cancer       Date:  2003-02-01       Impact factor: 6.860

9.  Tumor self-seeding by circulating cancer cells.

Authors:  Mi-Young Kim; Thordur Oskarsson; Swarnali Acharyya; Don X Nguyen; Xiang H-F Zhang; Larry Norton; Joan Massagué
Journal:  Cell       Date:  2009-12-24       Impact factor: 41.582

Review 10.  From genetic abnormality to metastases: murine models of breast cancer and their use in the development of anticancer therapies.

Authors:  P D Ottewell; R E Coleman; I Holen
Journal:  Breast Cancer Res Treat       Date:  2006-03       Impact factor: 4.872

View more
  45 in total

1.  Development of a metastatic murine colon cancer model.

Authors:  Krista P Terracina; Tomoyoshi Aoyagi; Wei-Ching Huang; Masayuki Nagahashi; Akimitsu Yamada; Kazunori Aoki; Kazuaki Takabe
Journal:  J Surg Res       Date:  2015-04-15       Impact factor: 2.192

2.  Engineered immune cells as highly sensitive cancer diagnostics.

Authors:  Amin Aalipour; Hui-Yen Chuang; Surya Murty; Aloma L D'Souza; Seung-Min Park; Gunsagar S Gulati; Chirag B Patel; Corinne Beinat; Federico Simonetta; Ivana Martinić; Gayatri Gowrishankar; Elise R Robinson; Eamon Aalipour; Zahra Zhian; Sanjiv S Gambhir
Journal:  Nat Biotechnol       Date:  2019-03-18       Impact factor: 54.908

Review 3.  Crosstalk between cancer cells and blood endothelial and lymphatic endothelial cells in tumour and organ microenvironment.

Authors:  Esak Lee; Niranjan B Pandey; Aleksander S Popel
Journal:  Expert Rev Mol Med       Date:  2015-01-30       Impact factor: 5.600

4.  Orthotopic Implantation Achieves Better Engraftment and Faster Growth Than Subcutaneous Implantation in Breast Cancer Patient-Derived Xenografts.

Authors:  Maiko Okano; Masanori Oshi; Ali Butash; Ichiro Okano; Katsuharu Saito; Tsutomu Kawaguchi; Masayuki Nagahashi; Koji Kono; Toru Ohtake; Kazuaki Takabe
Journal:  J Mammary Gland Biol Neoplasia       Date:  2020-02-27       Impact factor: 2.673

5.  Repurposing suramin for the treatment of breast cancer lung metastasis with glycol chitosan-based nanoparticles.

Authors:  Bei Cheng; Feng Gao; Erica Maissy; Peisheng Xu
Journal:  Acta Biomater       Date:  2018-12-05       Impact factor: 8.947

6.  Dissemination via the lymphatic or angiogenic route impacts the pathology, microenvironment and hypoxia-related drug response of lung metastases.

Authors:  Roben G Gieling; Richard J Fitzmaurice; Brian A Telfer; Muhammad Babur; Kaye J Williams
Journal:  Clin Exp Metastasis       Date:  2015-06-26       Impact factor: 5.150

7.  Type III Collagen Directs Stromal Organization and Limits Metastasis in a Murine Model of Breast Cancer.

Authors:  Becky K Brisson; Elizabeth A Mauldin; Weiwei Lei; Laurie K Vogel; Ashley M Power; Albert Lo; Derek Dopkin; Chand Khanna; Rebecca G Wells; Ellen Puré; Susan W Volk
Journal:  Am J Pathol       Date:  2015-03-17       Impact factor: 4.307

8.  Host sphingosine kinase 1 worsens pancreatic cancer peritoneal carcinomatosis.

Authors:  Hiroaki Aoki; Masayo Aoki; Eriko Katsuta; Rajesh Ramanathan; Michael O Idowu; Sarah Spiegel; Kazuaki Takabe
Journal:  J Surg Res       Date:  2016-07-09       Impact factor: 2.192

9.  Modified breast cancer model for preclinical immunotherapy studies.

Authors:  Eriko Katsuta; Stephanie C DeMasi; Krista P Terracina; Sarah Spiegel; Giao Q Phan; Harry D Bear; Kazuaki Takabe
Journal:  J Surg Res       Date:  2016-06-08       Impact factor: 2.192

10.  Murine breast cancer mastectomy model that predicts patient outcomes for drug development.

Authors:  Eriko Katsuta; Omar M Rashid; Kazuaki Takabe
Journal:  J Surg Res       Date:  2017-11       Impact factor: 2.192

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.